Back to Search
Start Over
Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial.
- Source :
-
Diabetes Care . Apr2019, Vol. 42 Issue 4, pe53-e55. 3p. - Publication Year :
- 2019
-
Abstract
- The article focuses on the study of retinopathy outcomes related to empagliflozin and placebo. It mentions that sodium–glucose cotransporter 2 (SGLT2) inhibitors can reduce cardiovascular (CV) events in CV outcome trials in type 2 diabetes patients. It mentions that the SGLT2 inhibitor empagliflozin decrease the risk of 3-point major adverse CV events.
- Subjects :
- *EMPAGLIFLOZIN
*PLACEBOS
*GLUCAGON-like peptide 1
Subjects
Details
- Language :
- English
- ISSN :
- 01495992
- Volume :
- 42
- Issue :
- 4
- Database :
- Academic Search Index
- Journal :
- Diabetes Care
- Publication Type :
- Academic Journal
- Accession number :
- 135476113
- Full Text :
- https://doi.org/10.2337/dc18-1355